Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 05, 2019 20:07 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs

COPENHAGEN, Denmark, March 05, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransConTM technology to address unmet medical...
March 04, 2019 16:01 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Proposed Public Offering of ADSs

COPENHAGEN, Denmark, March 04, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address unmet medical...
March 04, 2019 06:30 ET | Source: Ascendis Pharma A/S

Ascendis Pharma Announces Once-weekly TransCon™ Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency

- TransCon hGH demonstrated comparable safety and tolerability to a daily hGH - - Potential once-weekly treatment option to overcome long-standing challenges with administration of daily hGH - -...
February 28, 2019 20:20 ET | Source: Ascendis Pharma A/S

Ascendis Pharma Announces Orphan Drug Designation Granted for TransCon CNP as Treatment for Achondroplasia

COPENHAGEN, Denmark, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet...
February 11, 2019 17:27 ET | Source: Ascendis Pharma A/S

Ascendis Pharma Initiates Global Phase 2 Trial for TransCon PTH in Adult Subjects with Hypoparathyroidism

COPENHAGEN, Denmark, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet...
January 07, 2019 09:00 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Introduces Vision 3x3: A Strategic Roadmap Through 2025 to Achieve Sustainable Growth Using Multiple Approaches

COPENHAGEN, Denmark, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technologies to address significant...
December 21, 2018 16:01 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Participation in 37th Annual J.P. Morgan Healthcare Conference

COPENHAGEN, Denmark, Dec. 21, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon™ technology to address significant unmet...
November 28, 2018 16:05 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Reports Third Quarter 2018 Financial Results

- TransCon CNP preliminary phase 1 data support target product profile and further validates TransCon™ technology - - Diversified pipeline with three independent, clinically-validated rare disease...
November 28, 2018 16:01 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Positive Preliminary Phase 1 Data for TransCon CNP

- TransCon CNP delivered continuous exposure of CNP at target levels for seven days with a single subcutaneous administration - - TransCon CNP phase 1 results reinforce preclinical data and support...
November 14, 2018 16:15 ET | Source: Ascendis Pharma A/S

Ascendis Pharma A/S Announces Third Quarter 2018 Financial Results and Business Update Conference Call on November 28

COPENHAGEN, Denmark, Nov. 14, 2018 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq:ASND), a biopharmaceutical company that utilizes its innovative TransCon technology to address significant unmet...